USFDA approves Lupin Valbenazine Capsules
Mumbai: Global pharma major Lupin Limited has announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Valbenazine Capsules, 40 mg and 80 mg, to market a generic equivalent of Ingrezza Capsules, 40 mg and 80 mg, of Neurocrine Biosciences, Inc. “Lupin […]